17-alpha-Methyltestosterone powder

What is 17-alpha-Methyltestosterone Powder?
17a-Methyltestosterone(MT), a synthetic derivative of testosterone, is an androgenic preparation given by the oral route in a capsule form.

Methyltestosterone also known as 17-alpha-Methyltestosterone, 17a-MT, methyltest or as 17α-methylandrost-4-en-17β-ol-3-one, is a synthetic, orally active androgenic-anabolic steroid (AAS) and 17α-methylated derivative of testosterone that is used to treat males with androgen deficiency. It bears close structural similarity to testosterone, but has a methyl group at the C17α position in order to increase oral bioavailability. Due to efficient aromatization into the potent estrogen methylestradiol, 17-Methyltestosterone Powder has relatively high estrogenicity and hence potential side effects such as gynecomastia.




How does 17-Methyltestosterone Powder work?
17-alpha Methyltestosterone Powder is a testosterone replacement that acts like the natural sex hormone. Testosterone is responsible for the development and maintenance of many male features during and after puberty. Since Methyltestosterone Powder is a form of testosterone, it works by adding or replacing testosterone in the body to normal and healthy levels.

It’s unclear how Methyltestosterone Powder works to treat breast cancer, but it’s thought to slow the spread of the cancer in females by stopping tumor growth.


17 alpha Methyltestosterone Powder uses – What is Methyltestosterone(MT) Powder used for?
Medical use
17 alpha Methyltestosterone Powder is or has been used in the treatment of delayed puberty, hypogonadism, cryptorchidism, and erectile dysfunction in males, and in low doses to treat menopausal symptoms (specifically for osteoporosis, hot flashes, and to increase libido and energy), postpartum breast pain and engorgement, and breast cancer in women. It is specifically approved in the United States for the treatment of hypogonadism and delayed puberty in males and the treatment of advanced inoperable breast cancer in females. It was also approved in low doses in combination with esterified estrogens for the treatment of moderate to severe vasomotor symptoms associated with menopause in women in the United States, but this formulation was discontinued and hence is no longer used.